510(k) FDA Medical Device Regulatory Submission

The Challenge

A manufacturer pursuing FDA 510(k) clearance for a neurosurgical device faced significant delays.

The issue wasn’t just timing—it was risk. The device incorporated a new material not used in predicate devices, with direct brain contact and mechanical abrasion during use, raising serious FDA concerns.

At the same time, the submission itself wasn’t helping:

Poorly written documentation created confusion
Inadequate performance testing failed to support equivalence
FDA reviewers lacked a clear, defensible basis for clearance

Bottom line: The submission didn’t tell a convincing regulatory story—and the data didn’t back it up

The Solution

After stepping in, RQMIS identified three critical issues:

Root Cause Analysis
Right-Size the Evidence
Submitted a targeted 510(k) Response aligned with FDA expectations

Results: FDA 510(k) clearance achieved in under 6 months

510(k) Submission Repair: Accelerating Clearance Through Strategic Realignment

The 510(k) pathway is one of the most common routes for bringing a medical device to market in the United States. But speed to clearance depends on one thing above all: anticipating and addressing FDA concerns early and effectively.

In this case, a manufacturer’s 510(k) submission for a neurosurgical device had stalled. The product incorporated a new material not used in predicate devices, with direct contact with brain tissue and exposure to mechanical abrasion during normal use—raising significant regulatory concerns.

Root Causes of Delay

After replacing the original consultants, RQMIS identified three key issues:

Unaddressed material risk
The novel material introduced safety and performance concerns that were not adequately evaluated
Insufficient performance data
Testing did not demonstrate equivalence to the predicate device
Poor submission quality
The 510(k) was unclear and poorly structured, leading to FDA misunderstanding

The RQMIS Approach

RQMIS implemented a focused strategy to resolve both scientific and regulatory gaps:

1. Define the Right Evidence Pathway

Recommended an animal pre-clinical study to demonstrate equivalence
Avoided the need for a full clinical trial

2. Collaborate on Study Design

Partnered with the client’s CTO to develop a robust preclinical protocol

3. Engage the FDA Proactively

Submitted a Pre-Submission request
Conducted a teleconference with the FDA
Secured alignment on the proposed study and regulatory approach

4. Rebuild the Submission

Prepared and submitted a targeted 510(k) response
Ensured clarity, consistency, and technical accuracy through expert review

The Outcome

FDA 510(k) clearance achieved within 6 months
Timeline included design and execution of the animal study
Eliminated the need for a costly and time-intensive clinical trial

Key Takeaway

RQMIS successfully identified FDA concerns, aligned on the appropriate evidence strategy, and transformed a stalled submission into a cleared device—efficiently and cost-effectively